Targeting Small Molecule Delivery to the Brain and Spinal Cord via Intranasal Administration of Rabies Virus Glycoprotein (RVG29)-Modified PLGA Nanoparticles

Alternative routes of administration are one approach that could be used to bypass the blood–brain barrier (BBB) for effective drug delivery to the central nervous system (CNS). Here, we focused on intranasal delivery of polymer nanoparticles. We hypothesized that surface modification of poly(lactic-co-glycolic acid) (PLGA) nanoparticles with rabies virus glycoprotein (RVG29) would increase residence time and exposure of encapsulated payload to the CNS compared to non-targeted nanoparticles. Delivery kinetics and biodistribution were analyzed by administering nanoparticles loaded with the carbocyanine dye 1,1′-Dioctadecyl-3,3,3′,3′-Tetramethylindotricarbocyanine Iodide (DiR) to healthy mice. Intranasal administration yielded minimal exposure of nanoparticle payload to most peripheral organs and rapid, effective delivery to whole brain. Regional analysis of payload delivery within the CNS revealed higher delivery to tissues closest to the trigeminal nerve, including the olfactory bulb, striatum, midbrain, brainstem, and cervical spinal cord. RVG29 surface modifications presented modest targeting benefits to the striatum, midbrain, and brainstem 2 h after administration, although targeting was not observed 30 min or 6 h after administration. Payload delivery to the trigeminal nerve was 3.5× higher for targeted nanoparticles compared to control nanoparticles 2 h after nanoparticle administration. These data support a nose-to-brain mechanism of drug delivery that closely implicates the trigeminal nerve for payload delivery from nanoparticles via transport of intact nanoparticles and eventual diffusion of payload. Olfactory and CSF routes are also observed to play a role. These data advance the utility of targeted nanoparticles for nose-to-brain drug delivery of lipophilic payloads and provide mechanistic insight to engineer effective delivery vectors to treat disease in the CNS.

[1]  K. T. Householder,et al.  Fate of nanoparticles in the central nervous system after intrathecal injection in healthy mice , 2019, Scientific Reports.

[2]  Wei Wu,et al.  The Trigeminal Pathway Dominates the Nose-to-Brain Transportation of Intact Polymeric Nanoparticles: Evidence from Aggregation-Caused Quenching Probes. , 2019, Journal of biomedical nanotechnology.

[3]  G. Colombo,et al.  Surface-Modified Nanocarriers for Nose-to-Brain Delivery: From Bioadhesion to Targeting , 2018, Pharmaceutics.

[4]  R. Sirianni,et al.  Non-Enzymatic Tissue Homogenization for Biodistribution Analysis. , 2018, Methods in molecular biology.

[5]  P. Gamas,et al.  Laser Capture Micro-Dissection Coupled to RNA Sequencing: A Powerful Approach Applied to the Model Legume Medicago truncatula in Interaction with Sinorhizobium meliloti. , 2018, Methods in molecular biology.

[6]  P. McCarron,et al.  The potential use of rabies virus glycoprotein-derived peptides to facilitate drug delivery into the central nervous system: a mini review , 2017, Journal of drug targeting.

[7]  R. Bowser,et al.  Optical barcoding of PLGA for multispectral analysis of nanoparticle fate in vivo , 2017, Journal of controlled release : official journal of the Controlled Release Society.

[8]  B. Sarmento,et al.  Nose-to-brain delivery of BACE1 siRNA loaded in solid lipid nanoparticles for Alzheimer's therapy. , 2017, Colloids and surfaces. B, Biointerfaces.

[9]  Wei Wu,et al.  Evidence of nose-to-brain delivery of nanoemulsions: cargoes but not vehicles. , 2017, Nanoscale.

[10]  Youxin Li,et al.  Intranasal delivery of rotigotine to the brain with lactoferrin-modified PEG-PLGA nanoparticles for Parkinson’s disease treatment , 2016, International journal of nanomedicine.

[11]  Hemanta K Sharma,et al.  Nanosized Drug Delivery Systems for Direct Nose to Brain Targeting: A Review. , 2016, Recent patents on drug delivery & formulation.

[12]  K. T. Householder,et al.  A critical evaluation of drug delivery from ligand modified nanoparticles: Confounding small molecule distribution and efficacy in the central nervous system. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[13]  Barbara R. Conway,et al.  Nasal Drug Delivery Systems: An Overview , 2015 .

[14]  J. Ali,et al.  Nose-To-Brain Delivery of PLGA-Diazepam Nanoparticles , 2015, AAPS PharmSciTech.

[15]  Yiyun Huang,et al.  Radiolabeling of Poly(lactic-co-glycolic acid) (PLGA) Nanoparticles with Biotinylated F-18 Prosthetic Groups and Imaging of Their Delivery to the Brain with Positron Emission Tomography , 2014, Bioconjugate chemistry.

[16]  P. Djupesland,et al.  The nasal approach to delivering treatment for brain diseases: an anatomic, physiologic, and delivery technology overview. , 2014, Therapeutic delivery.

[17]  R. Ho,et al.  Aerosol-stable peptide-coated liposome nanoparticles: a proof-of-concept study with opioid fentanyl in enhancing analgesic effects and reducing plasma drug exposure. , 2014, Journal of pharmaceutical sciences.

[18]  Javed Ali,et al.  Insights into direct nose to brain delivery: current status and future perspective , 2014, Drug delivery.

[19]  R. Sirianni,et al.  PLGA Nanoparticles Formed by Single- or Double-emulsion with Vitamin E-TPGS , 2013, Journal of visualized experiments : JoVE.

[20]  Chandrakantsing V. Pardeshi,et al.  Direct nose to brain drug delivery via integrated nerve pathways bypassing the blood–brain barrier: an excellent platform for brain targeting , 2013, Expert opinion on drug delivery.

[21]  H. Okada,et al.  Intranasal Delivery of Camptothecin-Loaded Tat-Modified Nanomicells for Treatment of Intracranial Brain Tumors , 2012, Pharmaceuticals.

[22]  R. Thorne,et al.  Intranasal delivery of biologics to the central nervous system. , 2012, Advanced drug delivery reviews.

[23]  K. Sawant,et al.  Development and evaluation of olanzapine-loaded PLGA nanoparticles for nose-to-brain delivery: in vitro and in vivo studies. , 2011, Acta biomaterialia.

[24]  S. Upadhyay,et al.  Intranasal drug delivery system- A glimpse to become maestro , 2011 .

[25]  M. Lafon.  Rabies virus receptors , 2005, Journal of NeuroVirology.

[26]  W. Frey,et al.  Trigeminal pathways deliver a low molecular weight drug from the nose to the brain and orofacial structures. , 2010, Molecular pharmaceutics.

[27]  Chen Jiang,et al.  Brain-targeting gene delivery and cellular internalization mechanisms for modified rabies virus glycoprotein RVG29 nanoparticles. , 2009, Biomaterials.

[28]  Peter H Lin,et al.  Current advances in research and clinical applications of PLGA-based nanotechnology , 2009, Expert review of molecular diagnostics.

[29]  J. Hanes,et al.  Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. , 2009, Advanced drug delivery reviews.

[30]  D. V. Van Daele,et al.  Retrograde Labeling of the Rat Facial Nerve with Carbocyanine Dyes to Enhance Intraoperative Identification , 2008, The Annals of otology, rhinology, and laryngology.

[31]  Xinguo Jiang,et al.  Brain delivery of vasoactive intestinal peptide enhanced with the nanoparticles conjugated with wheat germ agglutinin following intranasal administration. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[32]  M. Y. Kim,et al.  Enhanced brain targeting efficiency of intranasally administered plasmid DNA: an alternative route for brain gene therapy , 2006, Journal of Molecular Medicine.

[33]  Yoji Yamashita,et al.  The "perivascular pump" driven by arterial pulsation is a powerful mechanism for the distribution of therapeutic molecules within the brain. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[34]  Ahmed Awad E. Ahmed,et al.  Carbamazepine uptake into rat brain following intra‐olfactory transport , 2006, The Journal of pharmacy and pharmacology.

[35]  Wei-Ping Zhang,et al.  Intranasal recombinant human erythropoietin protects rats against focal cerebral ischemia , 2005, Neuroscience Letters.

[36]  Dongxin Wang,et al.  Study on brain targeting of raltitrexed following intranasal administration in rats , 2005, Cancer Chemotherapy and Pharmacology.

[37]  R. G. Thorne,et al.  Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration , 2004, Neuroscience.

[38]  R. Thorne,et al.  Intranasal administration of interferon beta bypasses the blood–brain barrier to target the central nervous system and cervical lymph nodes: a non-invasive treatment strategy for multiple sclerosis , 2004, Journal of Neuroimmunology.

[39]  P. O'Byrne,et al.  Distribution of intranasal instillations in mice: effects of volume, time, body position, and anesthesia. , 2002, American journal of physiology. Lung cellular and molecular physiology.

[40]  P. Goadsby,et al.  GABA receptors modulate trigeminovascular nociceptive neurotransmission in the trigeminocervical complex , 2001, British journal of pharmacology.

[41]  S. P. Vyas,et al.  Endogenous carriers and ligands in non-immunogenic site-specific drug delivery. , 2000, Advanced drug delivery reviews.

[42]  W. Silver,et al.  Evidence for nicotinic acetylcholine receptors on nasal trigeminal nerve endings of the rat. , 2000, Chemical senses.

[43]  Y. Rahman,et al.  Delivery of Nerve Growth Factor to the Brain via the Olfactory Pathway. , 1998, Journal of Alzheimer's disease : JAD.

[44]  G. Ugolini,et al.  Propagation of pseudorabies virus in the nervous system of the mouse after intranasal inoculation. , 1994, Virology.

[45]  M. Bothwell,et al.  Nerve growth factor receptor (p75)‐immunoreactivity in the normal adult feline trigeminal system and following retrogasserian rhizotomy , 1993, The Journal of comparative neurology.

[46]  L. Astic,et al.  Spread of the CVS strain of rabies virus and of the avirulent mutant AvO1 along the olfactory pathways of the mouse after intranasal inoculation , 1991, Virology.

[47]  A. Aguayo,et al.  Persistent retrograde labeling of adult rat retinal ganglion cells with the carbocyanine dye diI , 1988, Experimental Neurology.

[48]  M. G. Honig,et al.  Fluorescent carbocyanine dyes allow living neurons of identified origin to be studied in long-term cultures , 1986, The Journal of cell biology.